WallStreetZenWallStreetZen

NASDAQ: XLO
Xilio Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for XLO

Based on 1 analyst offering 12 month price targets for Xilio Therapeutics Inc

Min Forecast
$2.00+284.62%
Avg Forecast
$2.00+284.62%
Max Forecast
$2.00+284.62%

Should I buy or sell XLO stock?

Based on 1 analyst offering ratings for Xilio Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although XLO's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates XLO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their XLO stock forecasts and price targets.

XLO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-06

1 of 1

Forecast return on equity

Is XLO forecast to generate an efficient return?

Forecast return on assets

Is XLO forecast to generate an efficient return on assets?

Company
N/A
Industry
120%

XLO earnings per share forecast

What is XLO's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.18
Avg 2 year Forecast
-$0.48

XLO revenue forecast

What is XLO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$82.6M+159.62%
Avg 2 year Forecast
$13.2M-58.59%
Avg 3 year Forecast
$3.8M-88.04%
XLO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

XLO revenue growth forecast

How is XLO forecast to perform vs Biotechnology companies and vs the US market?

Company
-50.73%
Industry
117.31%
Market
22.77%
XLO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XLO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XLO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XLO$0.55$2.00+266.30%Buy
BRNS$0.70$4.00+471.43%Buy
ANTX$1.06N/AN/A
SKYE$0.87$15.00+1,624.14%Buy
HYPD$3.65$5.88+60.96%Strong Buy
View Top Biotech Stocks

Xilio Therapeutics Stock Forecast FAQ

Is Xilio Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: XLO) stock is to Buy XLO stock.

Out of 1 analyst, 0 (0%) are recommending XLO as a Strong Buy, 1 (100%) are recommending XLO as a Buy, 0 (0%) are recommending XLO as a Hold, 0 (0%) are recommending XLO as a Sell, and 0 (0%) are recommending XLO as a Strong Sell.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.

What is XLO's earnings growth forecast for 2026-2027?

(NASDAQ: XLO) Xilio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Xilio Therapeutics's earnings in 2026 is -$58,489,000.On average, 2 Wall Street analysts forecast XLO's earnings for 2026 to be -$9,544,560, with the lowest XLO earnings forecast at -$9,261,058, and the highest XLO earnings forecast at -$9,922,562.

In 2027, XLO is forecast to generate -$25,452,159 in earnings, with the lowest earnings forecast at -$24,696,154 and the highest earnings forecast at -$26,460,165.

What is XLO's revenue growth forecast for 2026-2028?

(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of -50.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Xilio Therapeutics's revenue in 2026 is $31,804,000.On average, 2 Wall Street analysts forecast XLO's revenue for 2026 to be $4,334,847,082, with the lowest XLO revenue forecast at $4,206,063,778, and the highest XLO revenue forecast at $4,506,523,155. On average, 2 Wall Street analysts forecast XLO's revenue for 2027 to be $691,429,320, with the lowest XLO revenue forecast at $670,901,692, and the highest XLO revenue forecast at $718,834,491.

In 2028, XLO is forecast to generate $199,658,747 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $415,120,093.

What is XLO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: XLO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 119.5%.

What is XLO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year XLO price target, the average XLO price target is $2.00, with the highest XLO stock price forecast at $2.00 and the lowest XLO stock price forecast at $2.00.

The Wall Street analyst predicted that Xilio Therapeutics's share price could reach $2.00 by Aug 6, 2026. The average Xilio Therapeutics stock price prediction forecasts a potential upside of 266.3% from the current XLO share price of $0.55.

What is XLO's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: XLO) Xilio Therapeutics's current Earnings Per Share (EPS) is -$0.63. On average, analysts forecast that XLO's EPS will be -$0.18 for 2026, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at -$0.19. In 2027, XLO's EPS is forecast to hit -$0.48 (min: -$0.47, max: -$0.50).

What is XLO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: XLO) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.